Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of PXD101 (belinostat) when given in combination with azacitidine (when azacitidine is utilized at a dose range where its effects on cellular differentiation are known to be predominant) in patients with advanced hematologic cancers or other diseases.

SECONDARY OBJECTIVES:

I. Identify any additive or synergistic effects of this regimen on pharmacodynamic parameters, including apoptosis and re-expression of specific target genes.

II. Assess any evidence of clinical activity (complete remission, partial remission, hematologic improvement, stable disease) of this regimen in these patients.

OUTLINE: This is a dose-escalation study of belinostat followed by a randomized study.

Patients receive azacitidine subcutaneously (SC) and belinostat intravenously (IV) over 30 minutes on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of belinostat until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, additional patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (with trilineage dysplasia or arising from MDS) are randomized to 1 of 2 treatment arms.

Arm I: Patients receive azacitidine SC on days 1-5.

Arm II: Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After receiving one course, patients randomized to arm I may crossover to receive treatment on arm II.

For patients enrolled in the randomized portion of the study, bone marrow aspirates are obtained at baseline, and after course 1 for correlative studies. Samples are examined by gene expression analysis of p15 and p21, DNA methylation of p15INK4B, and apoptosis by RT-PCR and flow cytometry. Pharmacodynamic assays are also performed.

After completion of study treatment, patients are followed periodically for up to 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Accelerated Phase of Disease Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Blastic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia de Novo Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Previously Treated Myelodysplastic Syndrome Primary Myelofibrosis Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Disease Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (chemotherapy)

Patients receive azacitidine SC on days 1-5.

Group Type EXPERIMENTAL

Azacitidine

Intervention Type DRUG

Given SC

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Arm II (chemotherapy, enzyme inhibitor therapy)

Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.

Group Type EXPERIMENTAL

Belinostat

Intervention Type DRUG

Given IV

Azacitidine

Intervention Type DRUG

Given SC

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Belinostat

Given IV

Intervention Type DRUG

Azacitidine

Given SC

Intervention Type DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Beleodaq PXD 101 PXD101 5-AC 5-AZC U-18496

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of 1 of the following:

* Relapsed or refractory acute myeloid leukemia (AML)
* Relapsed or refractory acute promyelocytic leukemia (must have failed both tretinoin and arsenic trioxide)
* Relapsed or refractory acute lymphoblastic leukemia
* Secondary AML, including AML arising from antecedent hematologic diseases, such as myelodysplastic syndromes (MDS) or myeloproliferative disorders, OR therapy-related AML
* Chronic myelogenous leukemia in accelerated or blast phase
* Advanced phases of Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders, as defined by ≥ 1 of the following:

* Presence of anemia (hemoglobin \< 10 g/dL and/or red blood cell transfusion dependent)
* Presence of palpable splenomegaly
* MDS, including chronic myelomonocytic leukemia

* Must have intermediate or high-risk International Prognostic Scoring System (IPSS) scores (≥ 0.5)
* Low-risk IPSS scores allowed provided ≥ 1 of the following criteria are met:

* Hemoglobin \< 10 g/dL and/or red blood cell transfusion dependent
* Platelet count \< 50,000/mm³
* Absolute neutrophil count \< 1,000/mm³
* Refractory disease OR no standard therapy exists
* Evidence of AML associated with dysplasia on bone marrow histology for elderly patients (i.e., \> 60 years old) who are previously untreated and not candidates for or unwilling to undergoing induction therapy
* No known active CNS involvement with disease
* CALGB performance status (PS) 0-2 OR Karnofsky PS 60-100%
* Bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's syndrome)
* ALT ≤ 3 times upper limit of normal (unless due to disease)
* Creatinine ≤ 2 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101 or Azacitidine
* No history of allergic reactions to mannitol
* No history of dose-limiting toxicity during prior treatment with Azacitidine
* No concurrent uncontrolled illness including, but not limited to, the following:

* Ongoing or active infection
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia
* Psychiatric illness or social situation that would preclude compliance with study requirements
* No marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \> 500 msec)
* No long QT syndrome
* No uncontrolled cardiovascular disease, including the following:

* Severe uncontrolled hypertension
* Uncontrolled congestive heart failure related to primary cardiac disease
* Uncontrolled cardiac arrhythmia
* Uncontrolled ischemic or severe valvular heart disease
* Myocardial infarction within the past 6 months
* See Disease Characteristics
* Recovered from prior therapy
* At least 2 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
* At least 2 weeks since prior radiotherapy
* At least 4 weeks since prior investigational agents
* At least 24 hours since prior hydroxyurea
* At least 2 weeks since prior valproic acid
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent investigational agents
* No concurrent medication that may cause torsade de pointes
* No other concurrent anticancer therapy, including chemotherapy, radiotherapy, or biological agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olatoyosi Odenike

Role: PRINCIPAL_INVESTIGATOR

University of Chicago Comprehensive Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States

Site Status

University of Wisconsin Hospital and Clinics

Madison, Wisconsin, United States

Site Status

University Health Network-Princess Margaret Hospital

Toronto, Ontario, Canada

Site Status

Princess Margaret Hospital

Cashmere, Canterbury, New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada New Zealand